Clinical Trial Details

A Phase II Study of CPX-351 in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia

Categories (click each to see list of all clinical trials associated with that category): Leukemia/MDS/MPD (ONC)

Current Status: Open

Phase: II (Cancer Control)

Principal Investigator: Bhatt, Vijaya

Contact Information:
Marnee Strege
+1 402-559-8155
marnee.strege@unmc.edu

Eligibility: https://clinicaltrials.gov/study/NCT04269213?term=NCT04269213&rank=1

Summary
PRIMARY OBJECTIVE: I. To determine the complete response rate including morphologic complete remission (CR) and morphologic complete remission with incomplete blood count recovery (CRi) as defined by the International Working Group Criteria. SECONDARY OBJECTIVE: I. To determine CR + CRi duration, event free survival (EFS), overall survival (OS), patients successfully proceeding to allogenic hematopoietic cell transplant, and adverse events (AE).